{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:33Z","timestamp":1791407373351,"version":"4.3.3"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jfma.2015.04.001","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T17:30:42Z","timestamp":1437931842000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Current and novel therapeutic molecules and targets in Alzheimer's disease"],"prefix":"10.1016","volume":"115","author":[{"given":"Ashwini","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaluveelaveedu Murleedharan","family":"Nisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitrangda","family":"Silakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanukanti","family":"Anusha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nityasha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timir","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awanish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2015.04.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2013.04.006","article-title":"Alzheimer's disease facts and figures","volume":"9","author":"Alzheimer's Association","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jfma.2015.04.001_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jfma.2015.04.001_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front Neurol"},{"key":"10.1016\/j.jfma.2015.04.001_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-6606-4-3","article-title":"APP processing in Alzheimer's disease","volume":"4","author":"Zhang","year":"2011","journal-title":"Mol Brain"},{"key":"10.1016\/j.jfma.2015.04.001_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-94-007-5416-4_14","article-title":"Alzheimer's disease","volume":"65","author":"De-Paula","year":"2012","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.jfma.2015.04.001_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2796.2004.01386.x","article-title":"Multiple cognitive deficits during the transition to Alzheimer's disease","volume":"256","author":"B\u00e4ckman","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.jfma.2015.04.001_bib7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.neurol.2011.11.007","article-title":"The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive impairment, and dementia","volume":"168","author":"Croisile","year":"2012","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.jfma.2015.04.001_bib8","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2015.04.001_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jfma.2015.04.001_bib10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/157015911798376181","article-title":"Alzheimer's disease: Pathological mechanisms and recent insights","volume":"9","author":"Niedowicz","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jfma.2015.04.001_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease","volume":"27","author":"Lacor","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.jfma.2015.04.001_bib12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1126\/science.2218531","article-title":"Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides","volume":"250","author":"Yankner","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jfma.2015.04.001_bib13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.mehy.2004.02.031","article-title":"Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease","volume":"63","author":"Shen","year":"2004","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jfma.2015.04.001_bib14","first-page":"S7","article-title":"Neuropathologic changes in Alzheimer's disease","volume":"64","author":"Wenk","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jfma.2015.04.001_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2741\/2097","article-title":"The role of tau phosphorylation and cleavage in neuronal cell death","volume":"12","author":"Chun","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.jfma.2015.04.001_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2015.04.001_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archneur.65.3.329","article-title":"Genome-wide association studies in Alzheimer disease","volume":"65","author":"Waring","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jfma.2015.04.001_bib18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1471-4159.2006.04391.x","article-title":"FAD mutants unable to increase neurotoxic A\u03b2 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta","volume":"101","author":"Shioi","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.jfma.2015.04.001_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s001140100237","article-title":"Alzheimer's disease: molecular concepts and therapeutic targets","volume":"88","author":"Fassbender","year":"2001","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.jfma.2015.04.001_bib20","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","article-title":"Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jfma.2015.04.001_bib21","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jfma.2015.04.001_bib22","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/aps.2012.109","article-title":"Computational drug discovery","volume":"33","author":"Ou-Yang","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jfma.2015.04.001_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/0929867003375317","article-title":"Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry","volume":"7","author":"Ooms","year":"2000","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib24","unstructured":"Alzheimer's Association. Younger\/early onset Alzheimer's and dementia. https:\/\/www.alz.org\/national\/documents\/brochure_earlyonset.pdf [accessed 10.07.15]."},{"key":"10.1016\/j.jfma.2015.04.001_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","article-title":"Targeting acetylcholinesterase and butyrylcholinesterase in dementia","volume":"9","author":"Lane","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jfma.2015.04.001_bib26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1017\/S1041610211001116","article-title":"Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: a review","volume":"24","author":"Thompson","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.jfma.2015.04.001_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-0082(03)00089-3","article-title":"Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory","volume":"70","author":"Turner","year":"2003","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jfma.2015.04.001_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovi\u0107","year":"2013","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jfma.2015.04.001_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.phrs.2003.11.017","article-title":"Cholinesterase inhibitors: new roles and therapeutic alternatives","volume":"50","author":"Giacobini","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jfma.2015.04.001_bib30","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jfma.2015.04.001_bib31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.neurobiolaging.2013.09.029","article-title":"Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease","volume":"35","author":"Teipel","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jfma.2015.04.001_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5114\/fn.2013.37702","article-title":"What causes Alzheimer's disease?","volume":"51","author":"Armstrong","year":"2013","journal-title":"Folia Neuropathol"},{"key":"10.1016\/j.jfma.2015.04.001_bib33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1602\/neurorx.2.4.612","article-title":"Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease","volume":"2","author":"Jacobsen","year":"2005","journal-title":"Neuro Rx"},{"key":"10.1016\/j.jfma.2015.04.001_bib34","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1016\/j.bmc.2009.07.072","article-title":"Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors","volume":"17","author":"Sheng","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cbi.2009.06.024","article-title":"Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies","volume":"181","author":"Khan","year":"2009","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.jfma.2015.04.001_bib36","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.bmc.2012.09.005","article-title":"Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease","volume":"20","author":"Roy","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib37","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.bmc.2013.03.058","article-title":"Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives","volume":"21","author":"Basiri","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2012.09.030","article-title":"Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling","volume":"57","author":"Samadi","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejmech.2013.06.021","article-title":"Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease","volume":"67","author":"Samadi","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib40","first-page":"653962","article-title":"Virtual screening and biological evaluation of piperazine derivatives as human acetylcholinesterase inhibitors","volume":"2013","author":"Varadaraju","year":"2013","journal-title":"Int J Alzheimers Dis"},{"key":"10.1016\/j.jfma.2015.04.001_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1567205053585846","article-title":"The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism","volume":"2","author":"Lipton","year":"2005","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jfma.2015.04.001_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0031-6997(24)01394-2","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jfma.2015.04.001_bib43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","article-title":"Glutamate as a neurotransmitter in the healthy brain","volume":"121","author":"Zhou","year":"2014","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jfma.2015.04.001_bib44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","article-title":"Alzheimer's disease, \u03b2-amyloid, glutamate, NMDA receptors and memantine\u2013searching for the connections","volume":"167","author":"Danysz","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jfma.2015.04.001_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coph.2006.08.011","article-title":"NMDA receptor subunits: function and pharmacology","volume":"7","author":"Paoletti","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jfma.2015.04.001_bib46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease","volume":"24","author":"Parson","year":"2013","journal-title":"Neurotox Res"},{"key":"10.1016\/j.jfma.2015.04.001_bib47","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ejmech.2012.05.036","article-title":"3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies","volume":"54","author":"Colotta","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib48","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1747-0285.2012.01317.x","article-title":"1-Benzyl-1,2,3,4-tetrahydro-\u03b2-carboline as channel blocker of N-methyl-D-aspartate receptors","volume":"79","author":"Espinoza-Moraga","year":"2012","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.jfma.2015.04.001_bib49","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bmc.2013.12.040","article-title":"Synthesis, modeling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors","volume":"22","author":"Gitto","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/cbdd.12056","article-title":"Molecular modeling of a phenyl-amidine class of NMDA receptor antagonists and the rational design of new triazolyl-amidine derivatives","volume":"81","author":"Abreu","year":"2013","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.jfma.2015.04.001_bib51","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10822-009-9304-1","article-title":"Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists","volume":"23","author":"Krueger","year":"2009","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.jfma.2015.04.001_bib52","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/cmdc.200800124","article-title":"Computational studies to discover a new NR2B\/NMDA receptor antagonist and evaluation of pharmacological profile","volume":"3","author":"Gitto","year":"2008","journal-title":"Chem Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","article-title":"International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jfma.2015.04.001_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12264-013-1406-z","article-title":"M1 muscarinic acetylcholine receptor in Alzheimer's disease","volume":"30","author":"Jiang","year":"2014","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.jfma.2015.04.001_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1124\/pr.108.000562","article-title":"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection","volume":"61","author":"Buckingham","year":"2009","journal-title":"Pharmaol Rev"},{"key":"10.1016\/j.jfma.2015.04.001_bib56","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1021\/cn400086m","article-title":"Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits","volume":"4","author":"Davie","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.jfma.2015.04.001_bib57","first-page":"183","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia","volume":"10","author":"Foster","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jfma.2015.04.001_bib58","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.drudis.2013.09.005","article-title":"Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease","volume":"18","author":"Melancon","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jfma.2015.04.001_bib59","unstructured":"A randomized, double-blind, placebo-controlled, parallel, 24-week, Phase 2 study of three different doses of an alpha-7 nicotinic acetylcholine receptor agonist (EVP-6124) or placebo in subjects with mild to moderate probable Alzheimer's disease. Identifier No. NCT01073228. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01073228?term=NCT01073228&rank=1 [accessed 10.07.15]."},{"key":"10.1016\/j.jfma.2015.04.001_bib60","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s00018-005-5597-y","article-title":"Glycogen synthase kinase 3\u03b2 and Alzheimer's disease: pathophysiological and therapeutic significance","volume":"63","author":"Balaraman","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jfma.2015.04.001_bib61","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00018-007-7220-x","article-title":"Tauopathies","volume":"64","author":"Hernandez","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jfma.2015.04.001_bib62","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.1016\/j.bmcl.2013.09.021","article-title":"6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3\u03b2 inhibitors","volume":"23","author":"Uehara","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jfma.2015.04.001_bib63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jfma.2015.04.001_bib64","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2183\/pjab.89.321","article-title":"Metabolism of amyloid \u03b2 peptide and pathogenesis of Alzheimer's disease","volume":"89","author":"Saido","year":"2013","journal-title":"Proc Jpn Acad Ser"},{"key":"10.1016\/j.jfma.2015.04.001_bib65","first-page":"1","article-title":"The \u03b2-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease","volume":"3","author":"Vassar","year":"2013","journal-title":"Alz Res Ther"},{"key":"10.1016\/j.jfma.2015.04.001_bib66","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00216-011-4963-x","article-title":"Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in\u00a0vitro methods for characterization of inhibitors","volume":"400","author":"Mancini","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nurt.2008.05.007","article-title":"\u03b2\u2013Secretase as a therapeutic target for Alzheimer's disease","volume":"5","author":"Ghosh","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jfma.2015.04.001_bib68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","article-title":"Developing \u03b2-secretase inhibitors for treatment of Alzheimer's disease","volume":"120","author":"Ghosh","year":"2012","journal-title":"J Neurochem"},{"key":"10.1016\/j.jfma.2015.04.001_bib69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bmcl.2007.09.100","article-title":"Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds","volume":"18","author":"Piazzi","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jfma.2015.04.001_bib70","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.bmc.2008.12.067","article-title":"Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and \u03b2-secretase","volume":"17","author":"Zhu","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib71","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.bbagen.2008.01.017","article-title":"Flavonols and flavones as BACE-1 inhibitors: Structure \u2013 activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features","volume":"1780","author":"Shimmyo","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jfma.2015.04.001_bib72","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.bmc.2005.01.002","article-title":"Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with \u03b2-secretase","volume":"13","author":"Zuo","year":"2005","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib73","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00894-012-1656-0","article-title":"In\u00a0vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile","volume":"19","author":"Remya","year":"2013","journal-title":"J Mol Model"},{"key":"10.1016\/j.jfma.2015.04.001_bib74","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejmech.2013.03.021","article-title":"Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors","volume":"64","author":"Razavi","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib75","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1016\/j.bmc.2007.07.003","article-title":"Synthesis, in\u00a0vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and A\u03b2 1\u201342 aggregation for Alzheimer's disease therapeutics","volume":"15","author":"Kwon","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jfma.2015.04.001_bib76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bmcl.2012.11.011","article-title":"Novel peptidomimetics as BACE-1 inhibitors: Synthesis, molecular modeling, and biological studies","volume":"23","author":"Butini","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jfma.2015.04.001_bib77","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1016\/j.bmcl.2010.08.102","article-title":"Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model","volume":"20","author":"Truong","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jfma.2015.04.001_bib78","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1523\/JNEUROSCI.2884-10.2010","article-title":"A noncompetitive BACE1 inhibitor TAK-070 ameliorates A\u03b2 pathology and behavioral deficits in a mouse model of Alzheimer's disease","volume":"30","author":"Fukumoto","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.jfma.2015.04.001_bib79","unstructured":"A single-center, randomized, double-blinded, placebo-controlled, 4-way cross-over study to assess the effect of a single oral dose of AZD3293 administration on QTc interval compared to placebo, using open-label AVELOX (Moxifloxacin) as a positive control, in healthy male subjects. AZD3293 Trial. Identifier No. NCT02040987. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02040987?term=NCT02040987&rank=1 [accessed 10.07.15]."},{"key":"10.1016\/j.jfma.2015.04.001_bib80","unstructured":"A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 with a long term double-blind extension in subjects with mild to moderate Alzheimer's disease (Protocol No. MK-8931-017-10) (also known as SCH 900931, P07738). MK-8931 Trial. Identifier No. NCT01739348. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01739348?term=NCT01739348&rank=1 [accessed 10.07.15]."},{"key":"10.1016\/j.jfma.2015.04.001_bib81","first-page":"S27","article-title":"Investigational medications for treatment of patients with Alzheimer disease","volume":"110","author":"Potter","year":"2010","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.jfma.2015.04.001_bib82","unstructured":"Randomized, double-blind, placebo-controlled, parallel-group, 18-month safety and efficacy study of TRx0237 in subjects with mild Alzheimer's disease. TRx0237 trial. Identifier No. NCT01689233. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01689233?term=NCT01689233&rank=1 [accessed 10.07.15]."},{"key":"10.1016\/j.jfma.2015.04.001_bib83","unstructured":"TauRx Therapeutics Achieves Enrollment Target for Second Phase III Clinical Trial of LMTX\u2122 in Alzheimer's Disease. TauRx Therapeutics. http:\/\/taurx.com\/taurx-005-enrolment.html [accessed 10.07.15]."}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664615001497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664615001497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T18:21:50Z","timestamp":1748542910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664615001497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0929664615001497"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2015.04.001","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and novel therapeutic molecules and targets in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2015.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier (Singapore) Pte Ltd.","name":"copyright","label":"Copyright"}]}}